Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
8.25
-0.55 (-6.25%)
At close: Jun 5, 2026, 4:00 PM EDT
8.26
+0.01 (0.12%)
After-hours: Jun 5, 2026, 7:31 PM EDT
Ocular Therapeutix Employees
Ocular Therapeutix had 325 employees as of December 31, 2025. The number of employees increased by 51 or 18.61% compared to the previous year.
Employees
325
Change (1Y)
51
Growth (1Y)
18.61%
Revenue / Employee
$160,117
Profits / Employee
-$893,840
Market Cap
1.81B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 325 | 51 | 18.61% |
| Dec 31, 2024 | 274 | 7 | 2.62% |
| Dec 31, 2023 | 267 | -7 | -2.55% |
| Dec 31, 2022 | 274 | 46 | 20.18% |
| Dec 31, 2021 | 228 | 47 | 25.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| ADMA Biologics | 647 |
| AbCellera Biologics | 562 |
| Lakefront Biotherapeutics NV | 558 |
| Vericel | 398 |
| Intellia Therapeutics | 377 |
| Harmony Biosciences Holdings | 293 |
| Zymeworks | 243 |
OCUL News
- 13 hours ago - Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 1 day ago - Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026 - GlobeNewsWire
- 3 days ago - Ocular Therapeutix™ to Host Investor Day on June 17, 2026 - GlobeNewsWire
- 10 days ago - Ocular Therapeutix Transcript: Stifel 2026 Virtual Ophthalmology Forum - Transcripts
- 24 days ago - Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Ocular Therapeutix Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Ocular Therapeutix Earnings release: Q1 2026 - Filings
- 4 weeks ago - Ocular Therapeutix Quarterly report: Q1 2026 - Filings